Montelukast for Eczema: Why a Positive Subgroup Does Not Settle the Question
If you already take montelukast for asthma or nasal allergies, it is reasonable to ask whether it also helps eczema. The answer requires eczema-specific evidence. A medicine's usefulness for one associated condition does not establish its usefulness for another, and a favorable subgroup in a review is not a recommendation for every adult or child.
What the earlier randomized evidence found
The 2018 Cochrane review included five trials involving 202 participants, mainly adults, with treatment lasting four to eight weeks. All tested montelukast. Three placebo-controlled studies, involving 131 people, did not establish a difference in eczema severity; the evidence was rated low quality. Results against conventional treatment were inconsistent. This was short-term research, not evidence about years of control or routine infant care.
What changed in the 2025 review?
A 2025 review included 26 studies of different designs and 742 participants aged 1–70. Its overall severity result was not statistically significant. An adult subgroup favored montelukast on SCORAD, with a standardized mean difference of −0.94 (95% confidence interval −1.35 to −0.54). A comparison with conventional treatment also favored it, whereas the overall conclusion remained inconsistent.
The 742 people were not all participants in one randomized comparison, and not every included study entered the statistical pooling. Different designs, comparators and scoring tools limit interpretation. The adult subgroup is not proof of benefit in babies, children or every adult. It also does not turn a standardized difference into a 94% improvement.
| Statement in a review | How to read it |
|---|---|
| Overall result not significant | The analysis did not establish a reliable overall difference. |
| Adult subgroup favored treatment | A narrower finding needs confirmation and context. |
| Standardized mean difference | A scale-free effect size, not a percentage cured. |
| Some studies reported no adverse events | Small, short studies cannot exclude uncommon serious harms. |
The safety warning belongs in the same conversation
The FDA's March 4, 2020 communication describes a boxed warning about serious behavioral and mood changes with montelukast. It directs patients or caregivers to stop the medicine and contact a healthcare professional right away if these occur. This warning applies even when a prescription was issued for asthma or allergies; an eczema article should not minimize it.
Do not add, borrow or change the medicine solely because of a subgroup percentage. If it is already prescribed, ask which condition it treats, how benefit is assessed and what symptoms require immediate contact. A brief eczema study does not replace the product's safety information or your clinician's assessment.
Keep separate conditions and goals clear
Our guide to separate eczema and asthma plans explains why breathing treatment and skin treatment need their own instructions. Our allergy-medicine discussion concerns another drug class; montelukast is a leukotriene-receptor antagonist, not an antihistamine.
At a review, describe skin symptoms, sleep disruption, current topical use and any breathing or nasal symptoms separately. Ask whether the next step is to reassess the diagnosis, simplify an existing plan or consider a better-supported eczema option. A treatment decision should join evidence, individual benefit and safety rather than select whichever number looks most encouraging.
Apply the same standard to other claims
A statistically favorable result needs its population and endpoint attached. The homeopathy trial discussion shows why a positive primary outcome should be acknowledged without treating it as proof of every claimed benefit. Biological plausibility is a separate issue: our coal-tar mechanism review explains why a laboratory target does not establish a clinical response rate.
Sources and reading notes
Prepared by the Dr. Arsy Editorial Team. Sources checked November 8, 2026. Educational information; no independent clinician review is implied. PubMed indexing is not NIH endorsement. Researchers and organizations cited do not endorse #003. The image is an AI-created editorial scene based on the actual jar, not a patient photo or study result.